[Survival of bDMARDs in bionaive patients with rheumatoid arthritis: data from a retrospective 12-month follow-up].

E S Aronova Galina V Lukina Svetlana Glukhova G I Gridneva A V Kudryavtseva

Published in: Terapevticheskii arkhiv (2020)

Study showed that 45% of patients with RA continue treatment with first-time bDMARD for more than 12 months. The most common reason for discontinuation of therapy was its lack of effectiveness. The best survival rate of bDMARDs was observed in RTM and ABA. When selecting bDMARD in each case, it is necessary to take into account the continuity at all stages of treatment.

Keyphrases

rheumatoid arthritis
transcription factor
machine learning
systemic lupus erythematosus
data analysis
arabidopsis thaliana
interstitial lung disease